We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

MERIDIAN BIOSCIENCE

Meridian Bioscience manufactures, markets, and distributes diagnostic test kits, purified reagents and biopharmaceuti... read more Featured Products: More products

Download Mobile App





Meridian Bioscience Exhibits Curian Immunofluorescent Testing Platform at ECCMID 2022

By LabMedica International staff writers
Posted on 25 Apr 2022
Print article
Image: Curian fluorescent immunoassay platform is focused on gastrointestinal testing (Photo courtesy of Meridian Bioscience)
Image: Curian fluorescent immunoassay platform is focused on gastrointestinal testing (Photo courtesy of Meridian Bioscience)

Meridian Bioscience, Inc. (Cincinnati, OH, USA) exhibited its best-in-class immunoassay, molecular, and blood chemistry diagnostic solutions focused on gastrointestinal, neonatal, pediatrics, and respiratory conditions at ECCMID 2022.

Among its diagnostic solutions featured at ECCMID 2022 was Meridian’s Curian immunofluorescent testing platform focused in gastrointestinal testing that is packaged in a small footprint to improve hospital operational efficiencies. Curian boasts a simple workflow and clean sample handling to provide a rapid result that eliminates the subjectivity of traditional rapid immunoassay diagnostic tests. Curian provides healthcare systems a rapid fluorescent immunoassay diagnostic solution with a standardized, simplified workflow that eliminates subjectivity. Laboratories can eliminate workflow burdens and achieve optimal efficiency while delivering top-of-the-line patient care. The platform can be easily integrated into any laboratory or healthcare system.

Meridian also demonstrated different assays for gastrointestinal disease testing that can be run on the Curian immunofluorescent testing platform, including the Curian HpSA and Curian Campy assays. The Curian platform and Curian HpSA assay are designed to quickly detect Helicobacter pylori antigens in human stool using immunofluorescent technology. Curian HpSA is intended to aid in the diagnosis of H. pylori infection and to demonstrate loss of H. pylori antigen following treatment (i.e., confirmation of eradication). The immunofluorescent technology of the Curian platform provides an objective, rapid H. pylori result with state-of-the-art clinical sensitivity, specificity, and a lower limit of detection than traditional rapid immunoassay testing. Combined with LIS connectivity, the Curian solution helps to eliminate subjectivity by reducing user variability related to interpreting and reporting visually based test results.

The FDA-cleared Curian Campy assay is a rapid, qualitative fluorescent immunoassay for the detection of a Campylobacter-specific antigen including C. jejuni, C. coli, C. upsaliensis, and C. lari in human fecal specimens. The assay is designed for use on the Curian immunofluorescent testing platform assay and features an easy workflow and produces objective results in about 20 minutes. Curian Campy offers clinicians accurate and timely results to deliver appropriate care for patients infected with campylobacteriosis.

Related Links:
Meridian Bioscience, Inc. 

New
Gold Supplier
Renin Control
Lumipulse Renin Control
New
Gold Supplier
Infectious Diseases Controls
Multichem ID-SeroNeg
New
Infliximab Rapid Test
Quantum Blue Infliximab
New
Gold Supplier
Body Fluid Application
CellaVision Body Fluid Application

Print article

Channels

Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.